【DPHARMA 7148 交流专区】（前名 CCMDBIO）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2014	30/09/2013	30/09/2014	30/09/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	44,819	40,845	125,937	116,671
2	Profit/(loss) before tax	11,287	9,054	32,589	31,017
3	Profit/(loss) for the period	8,682	6,786	24,575	24,175
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,682	6,786	24,575	24,175
5	Basic earnings/(loss) per share (Subunit)	6.25	4.89	17.70	17.41
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	4.00	4.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3500		1.3100

icy97

马化工药业拟1.3亿 向马化工购6公司

财经新闻 财经  2014-11-28 09:55
（吉隆坡27日讯）马化工药业（CCMDBIO，7148，主板消费产品股）建议以1亿3332万5000令吉，向母公司马化工（CCM，2879，主板工业产品股）收购6家公司，并偿还由马化工预付高达1亿1179万8000令吉的欠款。

根据马化工药业文告，将收购的6家公司包括CCM药剂、Innovax、CCM国际（菲律宾）、新加坡CCM药剂、CCM药剂私人有限公司和Upha药剂制造公司。

该公司指出，由于本身产能已触顶，所以必须收购其他生产设备来提升产能。而收购目标目前使用率仅达30至40%，所以收购后可即刻提升生产力，省回扩建活动成本。

1配1发附加股

这也是配合持有马化工药业73.72%的大股东马化工的业务整合计划。

马化工计划把旗下药剂业务都整合在单一个体，综合资源，进而提升产品素质和营运效率等。

同时，马化工药业将发售附加股，以1配1的方式，发售达1亿3947万9500股新股，以筹集最高1亿9527万1300令吉的资金。

其中约1亿4000万令吉，将在附加股活动后12个月内，用来偿还银行贷款，最少5055万至5147万1000令吉作为厂房扩张用途，及380万令吉附加股费用。

配合附加股活动，该公司也建议扩大注册股本，从现有2亿股或1亿令吉，扩大至5亿股。【南洋网财经】

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	CCM DUOPHARMA BIOTECH BERHAD (“CCM DUOPHARMA” OR THE “COMPANY”) I.        PROPOSED ACQUISITION; II.        PROPOSED RIGHTS ISSUE; AND III.        PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL
On behalf of the Board of Directors of CCM Duopharma, RHB Investment Bank Berhad wishes to announce that the Company is proposing to undertake the following: (i) CCM Duopharma had on 27 November 2014 entered into the following agreements: (a) a conditional share sale agreement for the proposed acquisition of the entire equity interest in CCM Pharmaceuticals Sdn Bhd (“CCM Pharmaceuticals”) and Innovax Sdn Bhd (“Innovax”) from Chemical Company of Malaysia Berhad (“CCMB”) for an aggregate purchase consideration of RM17,600,000 together with the settlement of advances due from Innovax, and CCM Pharmaceuticals and its subsidiaries to CCMB and its subsidiaries (“CCMB Group”) amounting to RM10,655,000 based on 30 September 2014 to be settled via cash (“CCMD SSA”); (b) a conditional share sale agreement for the proposed acquisition of the entire equity interest in CCM International (Philippines), Inc (“CCM Philippines”) from CCM Investments Ltd, a wholly-owned subsidiary of CCMB (“CCM Investments”) for a purchase consideration of RM1,000 to be settled via cash (“Philippines Company SSA”); and (c) a conditional share sale agreement for the proposed acquisition of the entire equity interest in CCM Pharmaceuticals (S) Pte Ltd (“CCM Singapore”) from CCM International Sdn Bhd, a wholly-owned subsidiary of CCMB (“CCM International”) for a purchase consideration of RM2,417,000 together with the settlement of advances due from CCM Singapore to the CCMB Group amounting to RM27,000 based on 30 September 2014 to be settled via cash (“Singapore Company SSA”); and (ii) Duopharma (M) Sdn Bhd (“DMSB”), a wholly-owned subsidiary of CCM Duopharma had on 27 November 2014 entered into a conditional share sale agreement for the proposed acquisition of the entire equity interest in CCM Pharma Sdn Bhd (“CCM Pharma”) and Upha Pharmaceutical Manufacturing (M) Sdn Bhd (“Upha Pharmaceutical”) from CCMB for an aggregate purchase consideration of RM113,307,000 together with the settlement of advances due from CCM Pharma and Upha Pharmaceutical to the CCMB Group amounting to RM101,116,000 based on 30 September 2014 to be settled via cash (“DMSB SSA”), (hereinafter the CCMD SSA, the Philippines Company SSA, the Singapore Company SSA and the DMSB SSA are collectively referred to as the “SSAs”, the shares that are the subject matter of the SSAs are collectively referred to as the “Sale Shares”; and the aforesaid proposed acquisition of CCM Pharmaceuticals, Innovax, CCM Philippines, CCM Singapore, CCM Pharma and Upha Pharmaceutical are collectively referred to as the “Proposed Acquisition”). The total purchase consideration of the Sale Shares would amount to RM133,325,000 (“Purchase Consideration”) and the aforesaid settlement of advances would amount to RM111,798,000; (iii) CCM Duopharma proposes to undertake a renounceable rights issue of up to 139,479,500 new ordinary shares of RM0.50 each in CCM Duopharma (“Rights Share(s)”) on the basis of one (1) Rights Share for every one (1) existing ordinary share of RM0.50 each held in CCM Duopharma (“CCM Duopharma Share(s)” or “Share(s)”) on an entitlement date to be determined and announced later (“Entitlement Date”) (“Proposed Rights Issue”); and (iv) CCM Duopharma proposes to increase the authorised share capital of the Company from RM100,000,000 comprising 200,000,000 CCM Duopharma Sharesto RM250,000,000 comprising 500,000,0000 CCMDuopharma Shares and to amend the Memorandum of Association of the Company to accommodate the increase in the authorised share capital (“Proposed Increase in Authorised Share Capital”). (TheProposed Acquisition, Proposed Rights Issue and Proposed Increase in Authorised Share Capital are hereinafter collectively referred to as the “Proposals”). Further details on the Proposals are set out in the attachment enclosed. This announcement is dated 27 November 2014. http://www.bursamalaysia.com/market/listed-companies/company-announcements/1808521

Attachments Announcement.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2014	31/12/2013	31/12/2014	31/12/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	51,024	45,734	176,961	162,405
2	Profit/(loss) before tax	13,921	9,160	46,509	40,175
3	Profit/(loss) for the period	11,119	9,313	35,271	32,275
4	Profit/(loss) attributable to ordinary equity holders of the parent	11,119	9,313	35,271	32,275
5	Basic earnings/(loss) per share (Subunit)	8.01	6.71	25.41	23.25
6	Proposed/Declared dividend per share (Subunit)	14.50	13.50	18.50	17.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3900		1.3900

icy97

EX-date	27/05/2015
Entitlement date	29/05/2015
Entitlement time	05:00:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final Single Tier Dividend of 14.5 sen per ordinary share
Period of interest payment	to
Financial Year End	31/12/2014
Share transfer book & register of members will be	to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no	Tricor Investor Services Sdn Bhd Level 17, The Gardens North Tower Mid Valley City, Lingkaran Syed Putra 59200 Kuala Lumpur Telephone no.: 03-2264 3883
Payment date	25/06/2015
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	29/05/2015
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.145

icy97

受多项利好消息激励 CCM联合药业飙涨12%

二零一五年二月二十五日 晚上七时二十七分
（吉隆坡25日讯）CCM联合药业有限公司（CCMDBIO，7148，消费产品组）的股价在今日开市后一路走高，主要是受到2014年盈利强劲、派息和企业活动等利好因素所激励。

闭市时，该股升36仙或12.33%至3.28令吉，最高3.35令吉，最低2.99令吉，成交量仅51万6400股。

该集团在截至2014年12月31日止全年财政年，所取得的净利按年从3227万令吉增长9.3％至3527万令吉，主要是公立医院对药剂需求回升。

而营业额则由前期的1亿6240万令吉上涨8.9％至1亿7696万令吉。至于税前盈利是4651万令吉，较去年同期的4017万令吉上升15.7％。

该集团建议在2014财政年派发14.5仙或29%的末期免税股息。股息除权日期在2015年5月27日，而截止过户日期是2015年5月29日，至于支付日期则在2015年6月25日。

去年11月，它的母公司马化工有限公司（CCM，2879，工业产品组）宣布，计划出售位于国内、菲律宾和新加坡的6个制药单位予持股73.7％的CCM联合药业，涉及金额达1亿3330万令吉。【光华日报财经】

icy97

馬化學藥業2.45億購6藥劑資產通過

2015-03-12 10:56      
（雪蘭莪‧巴生11日訊）馬化學藥業（CCMDBIO,7148,主板消費品組）股東批准以約2億4千500萬令吉併購母公司馬化學（CCM,2879,主板工業產品組）6項藥劑資產，放眼2020年時出口市場由目前的10%擴展到介於15到20%。

料第三季完成

該公司首席執行員李奧納阿里夫在馬化學藥業股東特大會後說，這項併購行動料於第三季完成，預計最快6至12個月可展現協作效應，配合專攻更大出口市場，最大的改善盈利可於4至5年實現。

他說，預料第三季藥劑業務整合後的營業額達3億2千萬，其中馬化學藥業佔1億7千200萬令吉。

他指出，這項併購行動恰如其時，因目前馬化學藥業生產設施已接近80至82%，而受併購的藥劑資產產能只達30到35%，形成了互補與更大協作利益。

他強調，這項併購的協作性強，整合後的藥劑業在政府藥劑佔40至45%，出口佔10%，餘者為供應私人界。

目前，馬化學藥業在政府藥劑份額達55%左右、10%出口，其餘為私人界；馬化學的出口也同樣達10%，政府份額達20%，但強於私人界，份額達70%左右，因此協作效應強，為兩公司股東創造價值。

李奧納阿里夫表示：“整合藥劑業後，預計藥劑業主管人員將受保留。”

他認為，併購不但擴大產能和靈活性，以迎合非專利藥劑的不斷增長需求，也能擷取更大國內外市場。

他說，馬化學藥業賺益將保健全，因很多業務為利基性，如生物治療與生物製劑，特別是紅血球生成素（EPO）和胰島素等。

該公司預計第三季也將展開發1億3千948萬新股，以籌措約1億9千527萬令吉。（星洲日報／財經）

icy97

馬化學藥業‧鞏固國內擴大海外

2015-03-23 12:24      
併購母公司6項藥劑資產

馬化學藥業（CCMDBIO,7148,主板消費品組）預定第三季完成以約2億4千500萬令吉，併購母公司馬化學（CCM,2879,主板工業產品組）旗下6項藥劑資產的計劃，並在擴大產能與改善效益後，放眼2020年崛起為大馬最大銷量藥劑生產商，出口市場則由目前的10%擴展到約20%。

該集團首席執行員李奧納阿里夫指出，這項併購行動預計最快6至12個月可展現協作效應，配合專攻更大出口市場，4至5年可大大改善盈利。

他預計，第三季藥劑業務整合後的營業額達3億2千萬，其中馬化學藥業佔1億7千200萬令吉。

他接受訪問時形容，這項併購藥劑資產行動恰逢其時，因目前馬化學藥業生產設施使用率接近80至82%，而受併購的藥劑資產產能只達30到35%，這項行動也形成互補與更大協作利益。

他強調，這項併購的協作性強，整合後的藥劑業在政府藥劑佔40至45%，出口佔10%，餘者供應私人界。

目前，馬化學藥業在政府藥劑份額達55%左右、10%出口，其餘為私人界；馬化學的出口同樣達10%，政府份額達20%，但強於私人界，份額達70%左右，尤其在成藥（OTC）部份，協作效應強可為兩公司股東創造價值。

“併購可擴大產能和增強營運靈活性，不僅迎合非專利藥劑的不斷增長需求，也能擷取更大國內外市場。”

他說，馬化學藥業賺益將保健全，因很多業務為利基性，如生物治療（Biotheraphy）與生物製劑，特別是紅血球生成素（EPO）和胰島素等。

他預測這些產品可於2017至2018年，使營業額增長至逾3億令吉。

總之，併購的是土地與廠房，而Innovax則在格林瑪麗的研發設施，為馬化學藥業與馬化學負責研發工作，也外包印度進行藥劑開發。

該公司第三季也將發售1億3千948萬新股，以籌措約1億9千527萬令吉；其中1億4千萬令吉用以償還銀行貸款，5千147萬作為巴生廠房擴展，380萬作為企業活動開銷。

他說，併購馬化學萬宜之資產後，可增進產能迎合國內乃至區域之藥業需求，這也符合公司增產和為其汰舊廠房提供靈活度。

他強調，政府藥劑雖然重要，不過馬化學藥業也同樣重視私人界，特別是普通科執業醫生，最重要是要確保“藥醫分家”後，也能做到私人界這區塊的藥劑供應。

他說，一旦完成收購與展開資本開銷計劃，也會開拓澳洲與沙地阿拉伯的出口市場。

探討併購菲印資產

馬化學藥業目前出口至東盟、北非與中東區域的27國；目前在新加坡業務有利可圖，馬化學國際擁有菲律賓業務，菲律賓是已開放市場，可進口非專利藥劑。

他直言會探討併購菲律賓與印尼資產，先在當地設辦事處，以非常謹慎態度探討併購當地藥劑資產。

他指出，大馬是首要製造基地，不過可利用東盟共同技術劑量（ACTD），長遠探討利用這個機制轉移製造活動至岸外。

他預計併購第三季完成，並可於完成後，由以往的每年推展3至4項藥劑產品，擴展至每年推展6至8種藥品。

他謹慎樂觀看待藥劑業的成長，非專利藥品預料每年以6%至8%成長，主要是人們更注重保健、高齡化社會等。

誓成生物治療一哥

馬化學藥業中期投資於既定目標，即成為生物治療（Biotheraphy）的首屈一指大馬業者。

這是一個超過3億令吉的市場，目前仍無國內業者，馬化學藥業已在大馬投資首個生物注射劑罐裝設施（Biological Fill＆Finish），並擴展貯藏設施處理冷鏈產品，將持續投資以達致目標。

“長遠來說，將開發更龐大的東盟市場，大馬市場規模畢竟有限，這可能透過翻新設施攻打出口市場，或者潛在進行區域併購。”

展現最大競爭力
成本壓至最低

在闡述大馬藥劑生態時，李奧納阿里夫說，大馬是個開放的藥劑業國家，市場開放後挑戰更為嚴峻。只要你符合註冊規定，不管是中國、印度、印尼的藥劑，都可進入我國市場。

“我們的策略是要把成本抑至最低，展現最大競爭力。其次是開發利基產品，這也是這幾年盈利可持續主因。”

他說，2013至2014年營業額增長很快，這使生產設施構成壓力，若從零設立新生產設施可能緩不濟急，要到2019年才成事；有了這項併購後，只有35%至40%產能的馬化學萬宜廠房，便可即時為馬化學藥業用於擴大生產。

除此，與韓國臨床試驗用於治療腎臟病黎的生物治療，乃至與印度合作的治療以後將置於萬宜廠的同一屋簷下，這是未來基本佈局。

馬化學藥業3至4年前，在巴生建立了貨倉，由於業務增長迅速，貨倉已不敷應用，萬宜則有3英畝地的貨倉空間，只在萬宜廠隔鄰。

“基於法規嚴謹，若把藥劑儲存於外邊，具有安全性問題，萬宜的貨倉正好補足這方面需求。”

他指出，併購除顯現上述惠益，還持有馬化學旗下藥劑業務的4主要品牌，這些成藥（OTC）包括Champs、Proviton、Flavettes等。這個區塊的年銷售達6千500萬令吉。

談到馬化學旗下Upha與菲律賓業務的虧損，他說，這需確保藥業小股東與利益受捍衛，且是公平的交易與願買願賣者，兩方的利益都需獲得照顧。

談到受併購資產的估值，他說，有關估值純粹以資產作為估值，其次是有關組合是互補性的。

簡而言之，他說，這次收購資產包括3英畝土地與廠房，也獲格林瑪麗研發設施，和很多藥劑品牌及註冊的藥品。

併購後之佈局

李奧納阿里夫指出，3至4年前在巴生藥業廠房投資甚巨，大約每年2千萬左右，基於廠房已久，能擴展的長遠幅度畢竟有限。未來，每年將斥資資本開銷2千萬至3千萬令吉。

巴生廠房的確無法建立迎合全球標準的製造設施，因此，過去5年所購器材，將陸續轉移至萬宜新廠。

巴生廠房有兩部份，其一是已用80%至90%產能，另一產能用上60%，因此擴展的產能將是在頭一部份，料於2016年第二與笫三季擴展。目前巴生產能是每年10億藥丸，以24小時運作計。

他指出，萬宜有大規模生產設施，而巴生的藥業設施則是小型的；因此從效益角度看，萬宜廠的規模效益顯著，然而缺點是無註冊，而巴生廠生產規模趨小，但有很多藥物的註冊，因此互補性強。

“一旦巴生已屆滿之產能欲改建，其構思是採納小型製造模式，即能符合各種不同國家註冊，而產量也沒有萬宜那麼大，基本是用以驅動出口業務。”

他說，基於大馬法規限制，如果藥劑業不是在同一實體生產，從不同廠房轉移生產，以往需要18至24個月的法規鑑定與檢驗；一旦完成上述併購後，就縮短至6個月，因為兩個實體的製造結構已趨統一。

“另外，所有巴生製造資產，都能提昇至獲美國食品藥品監管局（USFDA）的藥業審核，因此更會放眼區域爭取更大市佔。”

他預計在整合藥劑業後，私人界藥劑份額會有高成長；已鑑定3至4產品，以在萬宜新廠生產。

他說，馬化學藥業的賺益策略，則是把製造移至萬宜，這樣可改善賺益，同時也釋放巴生更大產能，用於生產不同國家的藥劑產品。

他預期在上述併購後，基於更有效益和規模，將會改善賺益。打個比方指出，在巴生廠房的藥劑製造96%至97%回酬，而在萬宜則可達99%。

他直言，併購萬宜資產後，可利用萬宜的最大產能增加盈利；然而，要如何加強產能，也成為最大的挑戰，與領導隊伍不時在探討中。

“在收購完成後，最短6個月內，可把巴生局部製藥業務轉移至萬宜。”

他披露正與馬方積極討論一至兩項項目，以承包製造的名義，或者進口替代增加產能。

出口市場方面，其產品主要是滲透進新加坡政府的藥劑，菲律賓主要還是滲透在私人界的藥劑鏈，未進入政府區塊。

1月9日升任集團董事經理，加入公司團隊21年的李奧納阿里夫打趣表示：“從現在起，半夜會驚醒的縈繞心際問題，將是如何填補萬宜廠的產能，希望12至24個月將有更穩定的製造業務。”

藥劑業重視研發

李奧納阿里夫說，藥劑業由概念至良好點子，這可能需要5年時間才可轉化為正面現金流，這主要是囿於其開發時間和規定所限。

“在這樣的情況下，保住高效隊伍將確保藥劑業長遠成功，公司幸運的有一個穩定的領導，而且並肩合作達致多項策略。總體而言，公司的3年員工流動率低於同儕。”

“我始終篤信，每個員工都可為公司成功作出貢獻，因此在公司內培養團隊、共享願景，將可向一致的願景前進。”

除此，職場內尤應設立良好生態系統，讓員工獲公平機會、依各自能力邁向成功。

他形容，研發為藥劑業公司的“源頭活血”，基於藥劑新產品的醞釀期長及涉成本，研發是引領藥劑業未來成功的明燈，因而公司從營業額3%撥作研發用途。

“儘管是非專利藥物製造商，用作開發（development）居多，而不是原創性的研究（research）。”

“公司的挑戰是如何平衡產品組合，既照顧到衛生部需求甚殷的著名藥物，也迎合私人保健業的需求，願意看到過去5年推展的產品群，貢獻營業額的至少15%至20%。”

人力資本超級重要，這也是公司很專注的重點。基於藥劑業孕育期之考量，高表現隊伍非常重要。

“為保有領導隊伍，須提供足夠升職機會予實幹的具天份者。他們是公司的未來，須製造機會讓現有組合有成長契機，且給予培訓和經名師指導，以期未來負起更吃重責任。”

他強調，讓員工放眼全球發展，這樣才能讓職員深識與掌握未來的長遠契機，屆時交棒予新領導層；對現有領導隊伍而言，最大成就莫過於把強盛公司，交由賢能者接棒。

一半營收來自政府機構

李奧納阿里夫說，大馬政府是非專利藥最大消費者，非專利藥廉宜過原創產品，這讓大馬政府極大機會管控醫療成本。

“實際上，大馬政府已從“專利懸崖”（patent cliff）節省大筆款項。過去3至4年，輕易的節省1億令吉。”

他說，私人保健保險在馬發展迅速，保險業在私人醫療業朝向有素質非專利藥品，只是時間問題。

馬化學藥業一半營收由政府機構貢獻，餘者為私人界與出口銷售。相信這種產品組合有利於抗衡政府政策變迭的風險，公司也透過Lean Six Sigma措施管控成本，但不忘確保法規受遵守。

“保健的通膨是生命必須面對的事實，其中一項挑戰是幾乎所有藥劑業所用原料與器材，皆靠進口而有匯率波動風險，最近馬幣走疲，公司便以出口作為自然護盤。”

為進一步管控保健成本，所有正在開發的產品，皆有一個中心價（Price Point），既照顧公司的合理回酬，也確保客戶的價值。

擴大股票流通

李奧納阿里夫說，這次活動也擴大資產基礎，使流通市場的股隻更多，改善市場流通性，不會因小量持股變動而股價波動！

目前市場流通只有27%，上述活動後雖然流通率一樣，不過基於股本擴大，市場上所流通的股更多。目前流通的很多為組合持股，個人持股者只有15%。

他說，在以折價發新股後，有些股東可能會保留持股，而一些股東可能會在市場上售股，在市場上創造更多流通股隻。

他指出，這次收購藥劑資產交易並沒有即時進賬獲益，重點是可以快速擴展產能，並從這個基礎上，可在3至4年讓公司獲益與進賬，因此是較長遠的佈局。

“儘管如此，股東可從股息角度獲益，藥業每年派發74%至76%盈利股息，若沒有重大資本投資時，則會派出超出此百分比派息，平均派息為75%。”

他強調，未來將儘量以同樣款額派息，不過在百分比方面可能有些稀釋。

“回顧過往5年紀錄，皆能履行承諾回饋股東，希望股東繼續對管理層保持信心。”

外匯優勢非長久

李奧納阿里夫說，所有出口以美元計，若美元強勢不再，會有自然護盤；原料以美元計，皆來自中國．印度、歐洲等國。

談到政府訂單，他說，儘管這方面很穩定，不過競標的合約通常兩三年，因而價格的訂定很重要。

他強調，已整合後，出口將可由10%增長至20%（2020至2021年），這是可以達致的。

他也說：“藥業組合的平衡很重要，這可分化不少風險，而且在每個區塊都有市佔。”

談到市場，他說汶萊、新加坡與菲律賓都非常開放，在美元銷售方面，我國比較具競爭性；當然，若以美元銷售，買家也慣常要折價。（星洲日報／投資致富‧直擊CEO‧文：張啟華）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2015	31 Mar 2014	31 Mar 2015	31 Mar 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,599	40,495	45,599	40,495
2	Profit/(loss) before tax	12,198	11,175	12,198	11,175
3	Profit/(loss) for the period	8,969	8,365	8,969	8,365
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,969	8,365	8,969	8,365
5	Basic earnings/(loss) per share (Subunit)	6.43	6.03	6.43	6.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.4700		1.3900

icy97

仿制药需求强劲 马化工药业财报看高一线

财经新闻 财经  2015-05-28 11:01
（巴生27日讯）马化工药业（CCMDBIO，7148，主板消费产品股）指出，对于截至今年12月31日财年的增长前景保持乐观。

总执行长说：“我们仍然看好今年的表现，比起去年，我们更加正面，因为业绩将比去年更好，主要是一些原本在去年4月开始的大型合约，延迟到6月才开始。”

伦纳德阿立夫昨天在公司年度股东大会后，发表上述谈话。

他也说，仿制药的需求仍然强劲，主要是因为政府采购，这将支撑公司增长。

“约68%的销量来自政府，看起来有点高，但是值得注意的是，政府也消耗了近70%的仿制药数量。”

更新资产

与此同时，马化工药业将开始拓展，建一座新工厂来代替在巴生的旧工厂。

他指出：“我们计划更新资产，三年来，我们已换了新设备，设备的品质还是很好，只是建筑设施需要升级。”

“在新的工厂里，我们能够提高产能50%，目前的产能是一年生产20亿个药片。”

该公司计划拨出4000万至7000万令吉来建新工厂，这笔资金将从近期的附加股和银行贷款取得。【南洋网财经】

icy97

馬化工聯藥附加股 定價每股RM1.80

財經3 Jun 2015 23:00
（吉隆坡3日訊）馬化工聯藥（CCMDBIO，7148，主要板消費）為每持1股現有股，可認購1股附加股定價，每股發售價1.80令吉。

馬化工聯藥向馬證交所報備，將以1股配1附加股，發售高達1億3947萬9500附加股，定價為每股1.80令吉。

報備文件指出，有關發行價是以該股截至週二（2日）過去5天成交量加權平均市價（VWAMP）3.726令吉的折價34.85%。

該公司早前亦宣佈，將法定股本從1億令吉或2億股，提高至2億5000萬令吉或5億股。【中国报财经】

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCM DUOPHARMA" OR THE "COMPANY")I.        ACQUISITION; II.        RIGHTS ISSUE; ANDIII.        INCREASE IN AUTHORISED SHARE CAPITAL(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
This announcement should be read in conjunction with the earlier announcement made on 27 November 2014. Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 27 November 2014. Reference is made to the announcements dated 27 November 2014, 24 December 2014, 9 January 2015, 4 February 2015, 13 February 2015, 16 February 2015, 11 March 2015, 27 March 2015 and 25 May 2015 in relation to the Proposals. On behalf of the Board of Directors of CCM Duopharma, RHB Investment Bank Berhad (“RHBIB”) wishes to announce that the issue price for the Rights Shares has been fixed at RM1.80 per Rights Share. The issue price for the Rights Shares represents a discount of approximately 34.85% to the theoretical ex-rights price of CCM Duopharma Shares of RM2.763 based on the five (5)-day volume weighted average market price of CCM Duopharma Shares up to and including 2 June 2015 of RM3.726. This announcement is dated 3 June 2015.

icy97

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCM DUOPHARMA" OR THE "COMPANY")I.        ACQUISITION; II.        RIGHTS ISSUE; ANDIII.        INCREASE IN AUTHORISED SHARE CAPITAL(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
This announcement should be read in conjunction with the earlier announcement made on 27 November 2014. Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 27 November 2014. Reference is made to the announcements dated 27 November 2014, 24 December 2014, 9 January 2015, 4 February 2015, 13 February 2015, 16 February 2015, 11 March 2015, 27 March 2015, 25 May 2015 and 3 June 2015 in relation to the Proposals. On behalf of the Board of Directors of CCM Duopharma, RHB Investment Bank Berhad (“RHBIB”) is pleased to announce that the Company had on 5 June 2015 entered into an underwriting agreement with RHB Investment Bank Berhad to underwrite 37,146,608 Rights Shares representing approximately 26.63% of the total Rights Shares, for which no undertaking has been obtained from shareholders of CCM Duopharma. The balance of 102,332,892 Rights Shares or approximately 73.37% of the total Rights Shares represents the entitlement of CCM Marketing Sdn Bhd, the substantial shareholder of CCM Duopharma, under the Rights Issue, for which it has provided written undertaking to subscribe in full for its entitlement under the Rights Issue as at the entitlement date. This announcement is dated 5 June 2015.

icy97

EX-date	18 Jun 2015
Entitlement date	22 Jun 2015
Entitlement time	05:00 PM
Entitlement subject	Rights Issue
Entitlement description	Renounceable rights issue of 139,479,500 new ordinary shares of RM0.50 each in CCM Duopharma Biotech Berhad ("CCM Duopharma" or the "Company") ("Rights Share(s)") on the basis of one (1) Rights Share for every one (1) ordinary share of RM0.50 each in CCM Duopharma ("CCM Duopharma Share(s)") at 5.00 p.m. on 22 June 2015, at an issue price of RM1.80 per Rights Share ("Rights Issue")
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR SERVICES SDN BHD (.)Level 17, The Gardens North TowerMid Valley City, Lingkaran Syed Putra59200Kuala LumpurTel:0322643883Fax:0322821886
Payment date
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	22 Jun 2015
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Ratio
Ratio	1 : 1
Rights Issue/Offer Price	Malaysian Ringgit (MYR) 1.800
Par Value	Malaysian Ringgit (MYR) 0.500

Title/Description	RIGHTS ISSUE
Despatch date	24 Jun 2015
Date for commencement of trading of rights	23 Jun 2015
Date for cessation of trading of rights	30 Jun 2015
Date for announcement of final subscription result and basis of allotment of excess Rights Securities	15 Jul 2015
Listing Date of the Rights Securities	22 Jul 2015

Last date and time for	Date	Time
Sale of provisional allotment of rights	29 Jun 2015	at	05:00:00 PM
Transfer of provisional allotment of rights	02 Jul 2015	at	04:00:00 PM
Acceptance and payment	07 Jul 2015	at	05:00:00 PM
Excess share application and payment	07 Jul 2015	at	05:00:00 PM

icy97

马化工获2.45亿贷款

财经新闻 财经  2015-06-27 12:39
（吉隆坡26日讯）马化工药业（CCMDBIO，7148，主板消费产品股）获兴业回教银行提供2亿4512万令吉的融资便利，以向母公司马化工（CCM，2879，主板工业产品股）收购6家公司。

马化工药业今日在文告中指出，今日与兴业回教银行签署Murabahah融资便利协议，总达2亿4512万3000令吉，将分两批利用。

其中，首批总值1亿3332万5000令吉的资金，将用在收购CCM药剂、Innovax、CCM国际（菲律宾）、新加坡CCM药剂、CCM药剂和Upha药剂制造共6家公司。

第二批总达1亿1179万8000令吉的资金，则是偿还马化工之前预付予6家公司的总欠款。

为了配合马化工的业务整合计划，马化工药业在去年11月献议收购上述6家公司，同时，也可利用后者的生产设备，来解决本身产能触顶的问题。【南洋网财经】

Type	Announcement
Subject	OTHERS
Description	Facility Agreement with RHB Islamic Bank Berhad for Commodity Murabahah Term Financing-i Facility Up to the Aggregate Principal Limit of Ringgit Malaysia Two Hundred Forty Five Million One Hundred and Twenty Three Thousand (RM245,123,000.00) Only
1.           INTRODUCTION              This announcement should be read in conjunction with the earlier announcement made on 27 November 2014. Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 27 November 2014.               Reference is made to the announcements dated 27 November 2014, 24 December 2014, 9 January 2015, 4 February 2015, 13 February 2015, 16 February 2015, 11 March 2015, 27 March 2015, 25 May 2015, 3 June 2015, 5 June 2015, 8 June 2015, 9 June 2015 and 22 June 2015.              The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that the Company has entered into a Facility Agreement for Commodity Murabahah Term Financing of up to RM245,123,000.00 (“Facility”) with RHB Islamic Bank Berhad (“Bank”) on 26 June 2015. 2.         INFORMATION ON CCM DUOPHARMA BITOECH BERHAD             CCMD was incorporated in Malaysia on 23 August 2000 under the name of Duopharma Biotech Berhad and later assumed its present name on 8 June 2006. It was listed on the Main Board of Bursa Malaysia Securities Berhad on 11 October 2001.             CCMD is principally engaged in the manufacture and marketing of tablets, capsules and other pharmaceutical products. CCMD is a subsidiary of CCM Marketing Sdn Bhd (“CCMM”). CCMM is a wholly owned subsidiary of Chemical Company of Malaysia Berhad (“CCM”). 3.         PURPOSE OF THE FACILITY            The Facility will be utilized as follows:            (a)   Tranche 1                     RM133,325,000.00  will be utilized to finance CCMD’s acquisition of the following six (6) subsidiaries owned by CCM:                     (i) Upha Pharmaceutical Manufacturing (M) Sdn Bhd;                     (ii) CCM Pharmaceuticals Sdn Bhd                     (iii) Innovax Sdn Bhd                     (iv) CCM Pharma Sdn Bhd                      (v)  CCM Pharmaceuticals (S) Pte Ltd                      (vi) CCM International (Philippines) Inc                     collectively referred to as “Target Companies”.       (b)   Tranche 2               RM111,798,000.00 will be utilized for the settlement of intercompany advances, loans or any outstanding borrowings or indebtedness owing by the above six (6) companies to CCM. Tranche 1 Facility will be for a period of Twelve (12) months from the date of the initial/first disbursement of the Facility while Tranche 2 Facility will be for a period of Seven (7) years from the date of the initial/first disbursement of the Facility. 4.         SECURITY FOR THE FACILITY             The Facility shall be governed by the terms and conditions of the Commodity Murabahah Facility Agreement. Other security documents required by RHB Islamic Bank Berhad are as   follows:             (a)   Letter of Awareness from CCM that RHB Islamic Bank Berhad had granted the Facility to CCMD;             (b)   Negative pledge over the shares of Duopharma (M) Sdn Bhd, a wholly-owned subsibidary of CCMD and also the Target Companies;             (c)  Assignment/Charge over Designated Accounts of CCMD, including but not limited to Proceeds Accounts; and             (d)  A Letter of Undertaking by CCMM, the major shareholder of CCMD, to subscribe for its entitlements on rights shares arising from the Rights Issue Exercise. 5.      FINANCIAL EFFECT OF THE COMMODITY MURABAHAH TERM FINANCING FACILITY          (a)   Share Capital                  The Facility will not have any effect on the share capital of the Company and the shareholding of the substantial shareholders of the Company.          (b)   Net Assets                  The Facility will not have any material effect on the net assets of the CCMD Group for the financial year ending 31 December 2015.          (c)   Earnings                 The Facility will not have any material effect on the earnings of the CCMD Group for the financial year ending 31 December 2015. However, an amount of approximately     RM1.7 million  will be incurred for stamp duty, legal fees and related finance costs for financial year ending 31 December 2015. 6.      INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND PERSONS CONNECTED           None of the Directors and/or substantial shareholders of CCMD and persons connected have any interest, direct or indirect, in the Facility. 7.      DIRECTOR'S RECOMMENDATION          The Board, after careful deliberation, is of the opinion that Facility is in the best interest of the Company and CCMD Group in managing its cash flow and liquidity. 8.      APPROVAL REQUIRED          No approval from the relevant regulatory authority is required for the Facility from RHB Islamic Bank Berhad. In respect of the acquisition of the Target Companies and the Rights Issue Exercise, the Company’s shareholders’ approval was obtained on 11th March 2015 at the Company’s Extraordinary General Meeting duly convened. 9.      DOCUMENTS FOR INSPECTION          The relevant documents in relation to the Facility are available for inspection at the Registered Office of the Company at 13th Floor, Menara PNB, 201-A Jalan Tun Razak, 50400 Kuala Lumpur during normal office hours for a period of one month from the date of this announcement. This announcement is dated 26 June 2015

icy97

icy97 发表于 29-11-2014 04:54 PM
马化工药业拟1.3亿 向马化工购6公司

财经新闻 财经  2014-11-28 09:55

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCM DUOPHARMA" OR THE "COMPANY")I.        ACQUISITION; II.        RIGHTS ISSUE; ANDIII.        INCREASE IN AUTHORISED SHARE CAPITAL(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
This announcement should be read in conjunction with the earlier announcement made on 27 November 2014. Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 27 November 2014. Reference is made to the announcements dated 27 November 2014, 24 December 2014, 9 January 2015, 4 February 2015, 13 February 2015, 16 February 2015, 11 March 2015, 27 March 2015, 25 May 2015, 3 June 2015, 5 June 2015 and 22 June 2015 in relation to the Proposals. On behalf of the Board of Directors of CCM Duopharma, RHB Investment Bank Berhad wishes to announce that the Acquisition has been duly completed on 30 June 2015 based on the terms of the SSAs. This announcement is dated 30 June 2015.

icy97

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCM DUOPHARMA" OR THE "COMPANY")I.        ACQUISITION; II.        RIGHTS ISSUE; ANDIII.        INCREASE IN AUTHORISED SHARE CAPITAL(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
This announcement should be read in conjunction with the earlier announcement made on 27 November 2014. Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 27 November 2014. Reference is made to the announcements dated 27 November 2014, 24 December 2014, 9 January 2015, 4 February 2015, 13 February 2015, 16 February 2015, 11 March 2015, 27 March 2015, 25 May 2015, 3 June 2015, 5 June 2015, 22 June 2015 and 30 June 2015 in relation to the Proposals. On behalf of the Board of Directors of CCM Duopharma, RHB Investment Bank Berhad wishes to announce that as at the close of acceptance, excess application and payment for the Rights Issue at 5.00 p.m. on 7 July 2015 ("Closing Date"), the total acceptances and excess applications for the Rights Issue were 148,906,727 Rights Shares, which represents an over-subscription of 6.76% over the total number of 139,479,500 Rights Shares available for subscription under the Rights Issue. The details of the acceptances and excess applications received as at the Closing Date are set out below: No. of Rights Shares % Acceptances 137,518,243 98.59 Excess applications 11,388,484 8.17 Total acceptances and excess applications 148,906,727 106.76 Total Rights Shares available for subscription 139,479,500 100.00 Over-subscription 9,427,227 6.76 In allocating the excess Rights Shares, the Board has applied the following basis as set out in the Abridged Prospectus dated 22 June 2015: (i) firstly, to minimise the incidence of odd lots; (ii) secondly, for allocation to our Entitled Shareholders who have applied for the Excess Rights Shares on a pro-rata basis and in board lots, calculated based on their respective shareholdings as at the Entitlement Date; (iii) thirdly, for allocation to our Entitled Shareholders who have applied for the Excess Rights Shares on a pro-rata basis and in board lots, calculated based on the quantum of their respective Excess Rights Shares application; and (iv) fourthly, for allocation to renouncee(s) and/or transferee(s) who have applied for the Excess Rights Shares on a pro-rata basis and in board lots, calculated based on the quantum of their respective Excess Rights Shares application. This announcement is dated 15 July 2015.

icy97

CCM DUOPHARMA BIOTECH BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Rights Issue
Details of corporate proposal	Rights Issue
No. of shares issued under this corporate proposal	139,479,500
Issue price per share ($$)	Malaysian Ringgit (MYR)   1.8000
Par Value ($$)	Malaysian Ringgit (MYR)   0.500
Latest issued and paid up share capital after the above corporate proposal in the following
Units	278,959,000
Currency	Malaysian Ringgit (MYR) 139,479,500.000
Listing Date	22 Jul 2015

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2015	30 Jun 2014	30 Jun 2015	30 Jun 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	56,308	40,623	101,907	81,118
2	Profit/(loss) before tax	8,407	10,107	20,605	21,302
3	Profit/(loss) for the period	5,848	7,513	14,817	15,892
4	Profit/(loss) attributable to ordinary equity holders of the parent	5,848	7,513	14,817	15,892
5	Basic earnings/(loss) per share (Subunit)	4.19	5.41	10.59	11.45
6	Proposed/Declared dividend per share (Subunit)	4.00	4.00	4.00	4.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3600		1.3900

icy97

EX-date	13 Oct 2015
Entitlement date	16 Oct 2015
Entitlement time	05:00 PM
Entitlement subject	Interim Dividend
Entitlement description	Interim Single Tier Dividend of 4 sen per ordinary share
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	Tricor Investor Services Sdn BhdLevel 17, The Gardens North TowerMid Valley City, Lingkaran Syed Putra59200 Kuala LumpurTelephone No.: 03-2264 3883
Payment date	06 Nov 2015
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	16 Oct 2015
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0400
Par Value	Malaysian Ringgit (MYR) 0.500

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2015	30 Sep 2014	30 Sep 2015	30 Sep 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	79,372	44,819	181,279	125,937
2	Profit/(loss) before tax	11,621	11,287	32,226	32,589
3	Profit/(loss) for the period	8,623	8,682	23,440	24,575
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,623	8,682	23,440	24,575
5	Basic earnings/(loss) per share (Subunit)	5.17	6.25	14.04	17.07
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6100		1.3900

icy97

馬化工聯藥 末季淨利漲38%
  
2016年2月23日
（吉隆坡23日訊）馬化工聯藥（CCMDBIO，7148，主要板消費）去年收購6家製藥設備公司后，2015財年營業額漲53%，從1億7696萬令吉攀升至2億7068萬令吉，競標業務取得的政府醫院需求增長亦提振業績，全年淨利攀升10%至3878萬令吉。

該公司建議末季每股派息5.5仙，使全年股息增至9.5仙。

該公司截至12月底末季，淨利按年起38%至1534萬令吉，受惠于需求成長及其他收入增加；營業額漲75%，達8940萬令吉。

馬化工聯藥總執行長倫納德阿立夫發布文告指出，雖然令吉貶值將影響公司生產和營運成本，製藥領域需求料持穩。他估計匯率波動和經濟不穩定，或對製造賺幅帶來壓力。

在現有挑戰環境下，馬化工聯藥謹慎樂觀看待2016財年將交出讓人滿意表現。【中国报财经】

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2015	31 Dec 2014	31 Dec 2015	31 Dec 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	89,401	51,024	270,680	176,961
2	Profit/(loss) before tax	17,529	13,921	49,755	46,509
3	Profit/(loss) for the period	17,529	13,921	49,755	46,509
4	Profit/(loss) attributable to ordinary equity holders of the parent	15,335	11,119	38,775	35,271
5	Basic earnings/(loss) per share (Subunit)	9.19	8.01	19.17	25.41
6	Proposed/Declared dividend per share (Subunit)	5.50	14.50	9.50	18.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6200		1.3900